Table 3C.
Summary of results from network meta-analysis and traditional pairwise meta-analysis on volume depletion.
| OR 95% CI | Placebo | Dapagliflozin 2.5mg | Dapagliflozin 5mg | Dapagliflozin 10mg | Empagliflozin 10mg | Empagliflozin 25mg | Canagliflozin 100mg | Canagliflozin 300mg |
|---|---|---|---|---|---|---|---|---|
| Placebo | 0.027 (0.01, 67.00 |
1.60 (0.39, 6.80) |
1.20 (0.84, 2.30) |
1.10 (0.45, 2.60) |
1.30 (0.62, 2.70) |
1.70 (0.78, 3.90) |
2.50 (1.30, 4.90) |
|
| Dapagliflozin 2.5mg | 1.36 (0.24, 7.55) |
0.01 (0.00, 14.00 |
1.20 (0.03, 42.00) |
|||||
| Dapagliflozin 5mg | 0.94 (0.44,2.00) | 0.69 (0.12, 4.18) |
1.20 (0.37, 3.70) |
|||||
| Dapagliflozin 10mg | 1.06 (0.89,1.27) | 0.78 (0.14, 4.34) |
1.12 (0.53, 2.36) |
|||||
| Empagliflozin 10mg | 1.02 (0.81, 1.28) |
0.75 (0.13, 4.26) |
1.08 (0.49, 2.38) |
0.96 (0.72, 1.29) |
1.10 (0.48, 2.40) |
|||
| Empagliflozin 25mg | 1.13 (0.90, 1.41) |
0.83 (0.15, 4.71) |
1.20 (0.55, 2.62) |
1.07 (0.80, 1.42) |
1.10 (0.89, 1.38) |
|||
| Canagliflozin 100mg |
1.47 (1.08, 1.99) |
1.08 (0.19, 6.19) |
1.56 (0.69, 3.50) |
1.39 (0.97, 1.97) |
1.44 (0.98, 2.10) |
1.30 (0.89, 1.89) |
||
| Canagliflozin 300mg |
2.19 (1.66, 2.90) |
1.62 (0.28, 9.22) |
2.33 (1.04, 5.19) |
2.07 (1.49, 2.89) |
2.15 (1.50, 3.08) |
1.94 (1.36, 2.78) |
1.50 (1.16, 1.92) |
Summary of results from network meta-analysis and traditional pairwise meta-analysis on all-cause death.On the lower triangle, the column-defining treatment is compared to the row-defining treatment, and odds ratios (OR) < 1 favor the column-defining treatment. On the upper triangle, the row-defining treatment is compared to the column-defining treatment, and OR < 1 favor the row-defining treatment. To obtain ORs for comparisons in the opposite direction, reciprocals should be taken. To obtain ORs for comparisons in the opposite direction, reciprocals should be taken. Significant results are in bold.